	US 12,246,015 B2
	Alpha polyglutamated raltitrexed and uses thereof
Clet Niyikiza, Gulph Mills, PA (US); and Victor Mandla Moyo, Ringoes, NJ (US)
Assigned to L.E.A.F. HOLDINGS GROUP LLC, Gulph Mills, PA (US)
Appl. No. 16/967,283
Filed by L.E.A.F. HOLDINGS GROUP LLC, Gulph Mills, PA (US)
PCT Filed Feb. 7, 2019, PCT No. PCT/US2019/016978 § 371(c)(1), (2) Date Aug. 4, 2020, PCT Pub. No. WO2019/157133, PCT Pub. Date Aug. 15, 2019.
Claims priority of provisional application 62/702,732, filed on Jul. 24, 2018.
Claims priority of provisional application 62/764,943, filed on Aug. 17, 2018.
Claims priority of provisional application 62/630,671, filed on Feb. 14, 2018.
Claims priority of provisional application 62/627,741, filed on Feb. 7, 2018.
Claims priority of provisional application 62/662,374, filed on Apr. 25, 2018.
Prior Publication US 2021/0169884 A1, Jun. 10, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/64 (2017.01); A61K 31/517 (2006.01); A61K 47/69 (2017.01); A61P 35/00 (2006.01)

CPC A61K 31/517 (2013.01) [A61K 47/6911 (2017.08); A61P 35/00 (2018.01)]

26 Claims

1. A liposomal composition comprising a liposome encapsulating an alpha polyglutamated raltitrexed, wherein the polyglutamated raltitrexed comprises 2-10 glutamyl groups having alpha carboxyl group linkages, and wherein the liposome does not contain a targeting moiety having specific affinity for a surface antigen on a target cell.